Nuance Investments LLC Buys New Shares in Kenvue Inc. $KVUE

Nuance Investments LLC bought a new position in shares of Kenvue Inc. (NYSE:KVUE) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 713,402 shares of the company’s stock, valued at approximately $11,579,000. Kenvue makes up 1.2% of Nuance Investments LLC’s holdings, making the stock its 25th biggest holding.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Canvas Wealth Advisors LLC acquired a new position in Kenvue in the 3rd quarter valued at approximately $218,000. Azzad Asset Management Inc. ADV raised its stake in shares of Kenvue by 4.1% in the third quarter. Azzad Asset Management Inc. ADV now owns 316,828 shares of the company’s stock valued at $5,142,000 after purchasing an additional 12,515 shares in the last quarter. American Assets Inc. bought a new position in Kenvue in the third quarter worth $568,000. Smartleaf Asset Management LLC boosted its stake in Kenvue by 75.0% during the third quarter. Smartleaf Asset Management LLC now owns 11,330 shares of the company’s stock worth $185,000 after buying an additional 4,857 shares in the last quarter. Finally, Canada Post Corp Registered Pension Plan boosted its stake in Kenvue by 338.1% during the third quarter. Canada Post Corp Registered Pension Plan now owns 135,056 shares of the company’s stock worth $2,207,000 after buying an additional 104,227 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Trading Up 0.3%

Shares of KVUE stock opened at $18.12 on Monday. The company has a market capitalization of $34.72 billion, a P/E ratio of 24.16 and a beta of 0.59. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $25.17. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The firm has a 50-day moving average price of $17.24 and a 200 day moving average price of $17.83.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th will be paid a $0.2075 dividend. The ex-dividend date is Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.6%. Kenvue’s payout ratio is 110.67%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on KVUE shares. Deutsche Bank Aktiengesellschaft set a $18.00 price objective on shares of Kenvue in a research note on Friday, October 24th. Zacks Research raised shares of Kenvue from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. Evercore set a $18.00 price target on shares of Kenvue in a research report on Tuesday, October 28th. Canaccord Genuity Group reaffirmed a “hold” rating and set a $15.00 price objective (down from $26.00) on shares of Kenvue in a report on Wednesday, October 29th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a research note on Friday, January 9th. Four research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $19.46.

Insider Activity at Kenvue

In other Kenvue news, Director Jeffrey C. Smith purchased 3,200,000 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were acquired at an average cost of $17.37 per share, for a total transaction of $55,584,000.00. Following the transaction, the director directly owned 27,307,632 shares in the company, valued at approximately $474,333,567.84. The trade was a 13.27% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 0.17% of the stock is owned by insiders.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.